NDLI: Can HCV affect the efficacy of anti-HIV treatment?

Content Provider	Springer Nature Link
Author	Filippini, P. Coppola, N. Scolastico, C. Liorre, G. cera, R. Sagnelli, E. Piccini, F.
Copyright Year	2000
Abstract	To evaluate the impact of new antiretroviral combinations (HAART: Highly Active Anti Retroviral Therapy) on HCV replication and liver enzyme levels, we analysed the changes in HCV viremia and aminotransferase levels in HIV and HCV co-infected patients. Moreover, to evaluate the influence of HCV infection on the efficacy of HAART, we compared the virological, immunological and biochemical response to antiretroviral combinations in anti-HIV positive subjects with or without HCV infection. We enrolled eight consecutive outpatients with HIV-HCV coinfection and with indications for HAART (Group A). For each patient in group A, we selected an anti-HIV negative patient with indications for HAART, pair-matched for age, sex, risk factor for HIV infection, presumed duration of infection, number of CD4 cells, HIV viremia and treatment schedule (Group B). A statistically significant increase in CD4 in both groups was found at 1st, 3rd and 6th month of antiretroviral therapy. A decrease in HIV-RNA in both groups was observed at 1st and 6th month of treatment. The percentage of patients with undetectable HIV-RNA at the 1st month was higher in Group B than in Group A (8/8 vs. 3/8, p = 0.025). Basal HCV-RNA viremia was very high in each case and no variations during treatment were observed. During therapy the aminotransferase levels slightly decreased in Group A and consistently increased in Group B. In Group A the differences were not significant to the statistical analysis; in Group B the aminotransferase levels at 3st and 6th month were significantly higher than those observed at the baseline.
Starting Page	937
Ending Page	944
Page Count	8
File Format	PDF
ISSN	03048608
Journal	Archives of Virology
Volume Number	145
Issue Number	5
e-ISSN	14328798
Language	English
Publisher	Springer-Verlag
Publisher Date	2000-05-01
Publisher Place	Vienna
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Virology Medical Microbiology Infectious Diseases
Content Type	Text
Resource Type	Article
Subject	Virology Medicine

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Epidemiological aspects of HCV infection in HIV-infected individuals in Piauí State, Northeast Brazil

Natural occurrence of NS5B inhibitor resistance-associated variants in Brazilian patients infected with HCV or HCV and HIV

Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia

Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients

Variation analysis of E1 and E2 in HCV subtypes

SUMO1 depletion prevents lipid droplet accumulation and HCV replication

Association between IL7RA polymorphisms and the successful therapy against HCV in HIV/HCV-coinfected patients

Quantification and genotyping of serum HCV-RNA in patients with chronic hepatitis C undergoing interferon treatment

Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96

Can HCV affect the efficacy of anti-HIV treatment?

Similar Documents

Epidemiological aspects of HCV infection in HIV-infected individuals in Piauí State, Northeast Brazil

Natural occurrence of NS5B inhibitor resistance-associated variants in Brazilian patients infected with HCV or HCV and HIV

Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia

Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients

Variation analysis of E1 and E2 in HCV subtypes

SUMO1 depletion prevents lipid droplet accumulation and HCV replication

Association between IL7RA polymorphisms and the successful therapy against HCV in HIV/HCV-coinfected patients

Quantification and genotyping of serum HCV-RNA in patients with chronic hepatitis C undergoing interferon treatment

Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96

Can HCV affect the efficacy of anti-HIV treatment?